BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:infliximab-dyyb (Inflectra) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of infliximab-dyyb (Inflectra)\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06064864-9753@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:infliximab-dyyb (Inflectra): Phase na readout est. (NCT06064864)
DESCRIPTION:infliximab-dyyb (Inflectra)\, phase na\, Crohn's Disease.\nStud
 y: Efficacy and Safety of Formulation Switching Between SC Infliximab and 
 IV Infliximab in Patients With CD\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab-d
 yyb-inflectra#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06064864
URL:https://assetmemo.bio/drug/infliximab-dyyb-inflectra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
